Search Videos and More
News
Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.
Document
Treatment Guidelines: Patients With a History of Breast Cancer who Desire Pregnancy
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations for patients with a history of breast cancer who desire pregnancy.
News
Most Young Women Treated For Breast Cancer Can Have Children, Study Shows
In a study of nearly 200 young women who have survived breast cancer, most of those who tried to conceive were able to become pregnant and give birth.
News
Breast Cancer Trial Aims to Improve Treatment for Men
Over the past 30 years, outcomes have improved dramatically for women with breast cancer. There are many new treatments, including hormone therapies and CDK4/6 inhibitors. In contrast, there has been no improvement in the outcomes for men with breast cancer. And current guidelines don’t support the use of newer therapies in men. Male breast cancer accounts for just 1% of all cases of breast cancer. Advancing care for a rare group requires a focused effort, so Jose Pablo Leone, MD, has invested energy into designing and leading a clinical trial for men with breast cancer.
News
Antibody-Drug Conjugates: A Cancer Therapy Revolution
Dana-Farber researchers explore how a novel therapy may benefit patients
Document
Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.
News
Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction
Cancer-related and physical outcomes were similar between longer and shorter regimens, but patients reported less burden on life and finances with shorter treatment regimen.
News
Final Overall Study Analysis Continues to Show Benefit of Sacituzumab Govitecan in Advanced HR+ Breast Cancer
A novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.
Document
Treatment Guidelines: Elacestrant for Advanced Estrogen Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on February 24 and May 5, 2023 to discuss recommendations for the use of elacestrant in patients with advanced estrogen receptor-positive breast cancer.
Video
ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD
Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.
Video
ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD
Women with breast cancer shed pounds thanks to telephone-based weight loss program, clinical trial finds.
Video
ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD
Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.